No Data
Ningbo Menovo Pharmaceutical (603538.SH) subsidiary obtained the pharmaceutical registration certificate for Metformin and Vildagliptin Tablets (II).
Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary Ningbo Menovo TianKang Pharmaceutical Co., Ltd. (abbreviation...
Ningbo Menovo Pharmaceutical (603538.SH) and related personnel received a warning letter from the Ningbo Securities Regulatory Bureau.
Ningbo Menovo Pharmaceutical (603538.SH) announced that the company received a notice from the China Securities Regulatory Commission on December 3, 2024...
Ningbo Menovo Pharmaceutical (603538.SH) participated in the selection of Jiangsu Alliance for the fourth and fifth batches of national organized pharmaceutical centralized procurement.
ningbo menovo pharmaceutical (603538.SH) announced that recently, the official website of Jiangsu Provincial Medical Security Bureau released "The 4th-5th batch of national...
Earnings Troubles May Signal Larger Issues for Ningbo Menovo Pharmaceutical (SHSE:603538) Shareholders
Ningbo Menova Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
ningbo menovo pharmaceutical (603538.SH) released its performance for the first three quarters, with a net income of 63.2504 million yuan, a year-on-year increase of 15.97%.
Ningbo Menovo Pharmaceutical (603538.SH) released the third quarter report for 2024, with revenue for the first three quarters at 9.4...
Ningbo Menovo Pharmaceutical Co., Ltd.'s (SHSE:603538) Price Is Right But Growth Is Lacking
No Data
